International Hyaluronic Acid Viscosupplementation Physician Survey 2011
Over 100 orthopedic specialists were surveyed regarding their perceptions and usage of hyaluronic acid viscosupplementation during the 2011 American Academy of Orthopaedic Surgeons (AAOS) conference. This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid viscosupplement product, including single injection, 3-injection and 5-injection therapy regimes. Satisfaction with current offerings is examined in detail, along with the market penetration of single injection products. The data presented describes practice experience, practice volume and the attitudes of the respondents to the product, as well as how these factors interact. In addition to physician brand preference, this survey report describes the proportion of doctors who would be willing to switch to a single injection product like Genzyme’s Synvisc-One®. The results of the survey indicated a high degree of familiarity with the product within the physician community. There is a general divide in the U.S. medical community between HA brands that are used for a majority of procedures within a practice. The respondents were asked to rate their satisfaction with the various injection products. This in term was compared to the probability of switching brands, and the possible motivating reasons for doing so.
The executive summary of this report is also available for purchase.
The executive summary of this report is also available for purchase.
EXECUTIVE SUMMARY
1.1 OVERVIEW
1.2 RESPONDENT PRACTICE LOCATION
1.3 COMPETING BRANDS
1.4 PURCHASING CHANNELS
1.5 IMPORTANCE OF PRICING
1.6 SATISFACTION WITH SINGLE INJECTION
1.7 PURCHASING DECISIONS
1.8 TIME TO PAIN RELIEF AFTER HA TREATMENT
SURVEY HIGHLIGHTS
2.1 RESPONDENT CHARACTERISTICS
2.1.1 Doctor Profile
2.1.2 Purchasing Channel
2.2 RESPONSE SUMMARY
2.2.1 Attitudes Towards Products
2.2.2 Product Incentives
2.2.3 Patient Profile
2.2.4 Brand Preferences
RESEARCH METHODOLOGY
3.1 RESEARCH OVERVIEW
3.2 RESEARCH SERVICES
3.3 SURVEY METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Sample Population Preparation
Step 3: Preparation, Questionnaire Design & Administration
Step 4: Reporting and Analysis
Step 5: Customer Feedback
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS
4.1 QUESTION 1: YEARS OF PRACTICE
4.1.1 Practice Experience by Global Region
4.1.2 Country of Origin
4.2 QUESTION 2: HYALURONIC ACID (HA) VISCOSUPPLEMENT PATIENTS PER MONTH.
4.2.1 HA Patients per Month
4.2.2 Monthly HA Patients by Practice Experience
4.3 QUESTION 3: HA UTILIZATION BY BRAND
4.4 QUESTION 4:REASONS FOR CHOOSING HA BRAND
4.4.1 Reasons for Choosing Brand
4.4.2 Reasons for Choosing Brand by Brand Preference
4.5 QUESTION 5: LIKELIHOOD OF INCREASING SINGLE INJECTION USE
4.6 QUESTION 6: SATISFACTION WITH SINGLE INJECTION PRODUCTS
4.6.1 Satisfaction with Single Injection
4.6.2 Likelihood of Increasing Single Injection Use by Satisfaction
4.7 QUESTION 7: PERCENTAGE OF HA PATIENTS THAT SUBSEQUENTLY GO ON TO TOTAL KNEE ARTHROPLASTY (TKA)
4.8 QUESTION 8: TIME TO TKA AFTER HA AND CONSERVATIVE TREATMENTS
4.8.1 Time to TKA
4.8.2 Time to TKA by Surgical Volume
4.9 QUESTION 9: HA INJECTION TYPES USED BEFORE TKA
4.10 QUESTION 10: PERCEIVED BRAND PURCHASING INCENTIVES
4.11 QUESTION 11: NATURE OF INCENTIVES RECEIVED
4.12 QUESTION 12: REASONS TO SWITCH TO DIFFERENT HA BRAND
4.12.1 General Reasons to Switch Brands
4.12.2 Reasons to Switch Brands by Brand Attribute Preference
4.13 QUESTION 13: PATIENT GROUPS RECEIVING THE MOST BENEFIT FROM HA
4.14 QUESTION 14: IMPORTANCE OF PRICING
4.15 QUESTION 15: NATURE OF PURCHASING CHANNELS
4.15.1 Purchasing Channels
4.15.2 Importance of Pricing by Purchasing Channel
4.16 QUESTION 16: RESPONDENT CLINICAL SETTING
4.17 QUESTION 17 TO 18: TIME TO RELIEF AFTER TREATMENT
4.17.1 Question 17: Time to Relief After Single Injection Treatment
4.17.2 Question 18: Time to Relief After 3-Injection Treatment
4.17.3 Question 19: Time to Relief After 5-Injection Treatment
APPENDIX 1: SURVEY QUESTIONS
1.1 OVERVIEW
1.2 RESPONDENT PRACTICE LOCATION
1.3 COMPETING BRANDS
1.4 PURCHASING CHANNELS
1.5 IMPORTANCE OF PRICING
1.6 SATISFACTION WITH SINGLE INJECTION
1.7 PURCHASING DECISIONS
1.8 TIME TO PAIN RELIEF AFTER HA TREATMENT
SURVEY HIGHLIGHTS
2.1 RESPONDENT CHARACTERISTICS
2.1.1 Doctor Profile
2.1.2 Purchasing Channel
2.2 RESPONSE SUMMARY
2.2.1 Attitudes Towards Products
2.2.2 Product Incentives
2.2.3 Patient Profile
2.2.4 Brand Preferences
RESEARCH METHODOLOGY
3.1 RESEARCH OVERVIEW
3.2 RESEARCH SERVICES
3.3 SURVEY METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Sample Population Preparation
Step 3: Preparation, Questionnaire Design & Administration
Step 4: Reporting and Analysis
Step 5: Customer Feedback
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS
4.1 QUESTION 1: YEARS OF PRACTICE
4.1.1 Practice Experience by Global Region
4.1.2 Country of Origin
4.2 QUESTION 2: HYALURONIC ACID (HA) VISCOSUPPLEMENT PATIENTS PER MONTH.
4.2.1 HA Patients per Month
4.2.2 Monthly HA Patients by Practice Experience
4.3 QUESTION 3: HA UTILIZATION BY BRAND
4.4 QUESTION 4:REASONS FOR CHOOSING HA BRAND
4.4.1 Reasons for Choosing Brand
4.4.2 Reasons for Choosing Brand by Brand Preference
4.5 QUESTION 5: LIKELIHOOD OF INCREASING SINGLE INJECTION USE
4.6 QUESTION 6: SATISFACTION WITH SINGLE INJECTION PRODUCTS
4.6.1 Satisfaction with Single Injection
4.6.2 Likelihood of Increasing Single Injection Use by Satisfaction
4.7 QUESTION 7: PERCENTAGE OF HA PATIENTS THAT SUBSEQUENTLY GO ON TO TOTAL KNEE ARTHROPLASTY (TKA)
4.8 QUESTION 8: TIME TO TKA AFTER HA AND CONSERVATIVE TREATMENTS
4.8.1 Time to TKA
4.8.2 Time to TKA by Surgical Volume
4.9 QUESTION 9: HA INJECTION TYPES USED BEFORE TKA
4.10 QUESTION 10: PERCEIVED BRAND PURCHASING INCENTIVES
4.11 QUESTION 11: NATURE OF INCENTIVES RECEIVED
4.12 QUESTION 12: REASONS TO SWITCH TO DIFFERENT HA BRAND
4.12.1 General Reasons to Switch Brands
4.12.2 Reasons to Switch Brands by Brand Attribute Preference
4.13 QUESTION 13: PATIENT GROUPS RECEIVING THE MOST BENEFIT FROM HA
4.14 QUESTION 14: IMPORTANCE OF PRICING
4.15 QUESTION 15: NATURE OF PURCHASING CHANNELS
4.15.1 Purchasing Channels
4.15.2 Importance of Pricing by Purchasing Channel
4.16 QUESTION 16: RESPONDENT CLINICAL SETTING
4.17 QUESTION 17 TO 18: TIME TO RELIEF AFTER TREATMENT
4.17.1 Question 17: Time to Relief After Single Injection Treatment
4.17.2 Question 18: Time to Relief After 3-Injection Treatment
4.17.3 Question 19: Time to Relief After 5-Injection Treatment
APPENDIX 1: SURVEY QUESTIONS
LIST OF FIGURES
EXECUTIVE SUMMARY
SURVEY HIGHLIGHTS
RESEARCH METHODOLOGY
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS
Figure 4-1: Years of Practice, 2011
Figure 4-2: Country of Origin, Asia, 2011
Figure 4-3: Country of Origin, Europe, 2011
Figure 4-4: Country of Origin, Latin America, 2011
Figure 4-5: Country of Origin, Africa, Middle East and Caribbean, 2011
Figure 4-6: HA Patients Treated per Month, 2011
Figure 4-7: Monthly HA Patients Seen by Years of Practice, 2011
Figure 4-8: Weighted Average for HA Brand Frequency of Use, Asia, 2011
Figure 4-9: Weighted Average for HA Brand Frequency of Use, Europe, 2011
Figure 4-10: Weighted Average for HA Brand Frequency of Use, Latin America, 2011
Figure 4-11: Weighted Average for HA Brand Frequency of Use, Other, 2011
Figure 4-12: Reasons for Choosing a HA Brand, 2011
Figure 4-13: Reasons for Choosing Brand by Brand Choice, Asia, 2011
Figure 4-14: Reasons for Choosing Brand by Brand Choice, Europe, 2011
Figure 4-15: Reasons for Choosing Brand by Brand Choice, Latin America, 2011
Figure 4-16: Reasons for Choosing Brand by Brand Choice, Middle East, Africa and Caribbean
Figure 4-17: Likelihood of Switching to Single Injection, 2011
Figure 4-18: Satisfaction with Single Injection Products, 2011
Figure 4-19: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Figure 4-20: Percentage of HA Patients that Subsequently Go on to Total Knee Arthroplasty (TKA), 2011
Figure 4-21: Time to TKA After HA and Conservative Treatments, Months, 2011
Figure 4-22: Time to TKA in Months per Percentage of Patients that Require TKA, 2011
Figure 4-23: HA Injection Types Used Before TKA, Weighted Average, 2011
Figure 4-24: HA Injection Types Used Before TKA by Response Distribution, Asia
Figure 4-25: HA Injection Types Used Before TKA by Response Distribution, Europe, 2011
Figure 4-26: HA Injection Types Used Before TKA by Response Distribution, Latin America, 2011
Figure 4-27: HA Injection Types Used Before TKA by Response Distribution, Other, 2011
Figure 4-28: Perceived Brand Purchasing Incentives, 2011
Figure 4-29: Nature of Incentives Received, 2011
Figure 4-30: Reasons to Switch to Different HA Brand, 2011
Figure 4-31: Nature of Incentives Received by Brand Selection Preferences, Asia, 2011
Figure 4-32: Nature of Incentives Received by Brand Selection Preferences, Europe, 2011
Figure 4-33: Nature of Incentives Received by Brand Selection Preferences, Latin America, 2011
Figure 4-34: Nature of Incentives Received by Brand Selection Preferences, Middle East, Africa and Caribbean, 2011
Figure 4-35: Patient Groups Receiving the Most Benefit from HA, 2011
Figure 4-36: Importance of Pricing, 2011
Figure 4-37: Purchasing Channels, 2011
Figure 4-38: Importance of Pricing by Purchasing Channel, Asia, 2011
Figure 4-39: Importance of Pricing by Purchasing Channel, Europe, 2011
Figure 4-40: Importance of Pricing by Purchasing Channel, Latin America, 2011
Figure 4-41: Importance of Pricing by Purchasing Channel, Middle East Africa and Caribbean, 2011
Figure 4-42: Respondent Clinical Setting, 2011
Figure 4-43: Time to Relief After Single Injection Treatment, Weeks, 2011
Figure 4-44: Time to Relief After 3-Injection Treatment, Weeks, 2011
Figure 4-45: Time to Relief After 5-Injection Treatment, Weeks, 2011
APPENDIX 1: SURVEY QUESTIONS
LIST OF CHART'S
EXECUTIVE SUMMARY
Chart 1-1: Hyaluronic Acid Usage Among Survey Respondents, Latin America, 2011
Chart 1-2: Respondent Location by Region, 2011
Chart 1-3: Brand Preference Among, Africa, Middle East and Caribbean, 2011
Chart 1-4: Purchasing Channels, Global, 2011
Chart 1-5: Perceived Importance of Pricing, Global, 2011
Chart 1-6: Likelihood of Increasing Single Injection Use as a function of Satisfaction Rating, Asia, 2011
Chart 1-7: Reasons for Choosing a HA Brand, Europe, 2011
Chart 1-8: Time to Pain Relief in Weeks, 3-Injection Therapy, 2011
SURVEY HIGHLIGHTS
RESEARCH METHODOLOGY
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS
Chart 4-1: Years of Practice, 2011
Chart 4-2: Respondents by Global Region, 2011
Chart 4-3: Country of Origin, Asia, 2011
Chart 4-4: Country of Origin, Europe, 2011
Chart 4-5: Country of Origin, Latin America, 2011
Chart 4-6: Country of Origin, Africa, Middle East and Caribbean, 2011
Chart 4-7: HA Patients per Month, 2011
Chart 4-8: Monthly HA Patients Seen by Years of Practice, 2011
Chart 4-9: Weighted Average for HA Brand Frequency of Use, Asia, 2011
Chart 4-10: Weighted Average for HA Brand Frequency of Use, Europe, 2011
Chart 4-11: Weighted Average for HA Brand Frequency of Use, Latin America, 2011
Chart 4-12: Weighted Average for HA Brand Frequency of Use, Other, 2011
Chart 4-13: Reasons for Choosing a HA Brand, 2011
Chart 4-14: Reasons for Choosing Brand by Brand Choice, Asia, 2011
Chart 4-15: Reasons for Choosing Brand by Brand Choice, Europe, 2011
Chart 4-16: Reasons for Choosing Brand by Brand Choice, Latin America, 2011
Chart 4-17: Reasons for Choosing Brand by Brand Choice, Middle East, Africa and Caribbean
Chart 4-18: Likelihood of Switching to Single Injection, 2011
Chart 4-19: Satisfaction with Single Injection Products
Chart 4-20: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-21: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-22: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-23: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-24: Percentage of HA Patients that Subsequently Go on to Total Knee Arthroplasty (TKA), 2011
Chart 4-25: Time to TKA After HA and Conservative Treatments, 2011
Chart 4-26: Time to TKA in Months per Percentage of Patients that Require TKA, Asia, 2011
Chart 4-27: Time to TKA in Months per Percentage of Patients that Require TKA, Europe, 2011
Chart 4-28: Time to TKA in Months per Percentage of Patients that Require TKA, Latin America, 2011
Chart 4-29: Time to TKA in Months per Percentage of Patients that Require TKA, Africa, Middle East and Caribbean, 2011
Chart 4-30: HA Injection Types Used Before TKA, Weighted Average, 2011
Chart 4-31: Perceived Brand Purchasing Incentives, 2011
Chart 4-32: Nature of Incentives Received, 2011
Chart 4-33: Reasons to Switch to Different HA Brand, 2011
Chart 4-34: Patient Groups Receiving the Most Benefit from HA, 2011
Chart 4-35: Importance of Pricing, 2011
Chart 4-36: Purchasing Channels, 2011
Chart 4-37: Respondent Clinical Setting, 2011
APPENDIX 1: SURVEY QUESTIONS
EXECUTIVE SUMMARY
SURVEY HIGHLIGHTS
RESEARCH METHODOLOGY
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS
Figure 4-1: Years of Practice, 2011
Figure 4-2: Country of Origin, Asia, 2011
Figure 4-3: Country of Origin, Europe, 2011
Figure 4-4: Country of Origin, Latin America, 2011
Figure 4-5: Country of Origin, Africa, Middle East and Caribbean, 2011
Figure 4-6: HA Patients Treated per Month, 2011
Figure 4-7: Monthly HA Patients Seen by Years of Practice, 2011
Figure 4-8: Weighted Average for HA Brand Frequency of Use, Asia, 2011
Figure 4-9: Weighted Average for HA Brand Frequency of Use, Europe, 2011
Figure 4-10: Weighted Average for HA Brand Frequency of Use, Latin America, 2011
Figure 4-11: Weighted Average for HA Brand Frequency of Use, Other, 2011
Figure 4-12: Reasons for Choosing a HA Brand, 2011
Figure 4-13: Reasons for Choosing Brand by Brand Choice, Asia, 2011
Figure 4-14: Reasons for Choosing Brand by Brand Choice, Europe, 2011
Figure 4-15: Reasons for Choosing Brand by Brand Choice, Latin America, 2011
Figure 4-16: Reasons for Choosing Brand by Brand Choice, Middle East, Africa and Caribbean
Figure 4-17: Likelihood of Switching to Single Injection, 2011
Figure 4-18: Satisfaction with Single Injection Products, 2011
Figure 4-19: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Figure 4-20: Percentage of HA Patients that Subsequently Go on to Total Knee Arthroplasty (TKA), 2011
Figure 4-21: Time to TKA After HA and Conservative Treatments, Months, 2011
Figure 4-22: Time to TKA in Months per Percentage of Patients that Require TKA, 2011
Figure 4-23: HA Injection Types Used Before TKA, Weighted Average, 2011
Figure 4-24: HA Injection Types Used Before TKA by Response Distribution, Asia
Figure 4-25: HA Injection Types Used Before TKA by Response Distribution, Europe, 2011
Figure 4-26: HA Injection Types Used Before TKA by Response Distribution, Latin America, 2011
Figure 4-27: HA Injection Types Used Before TKA by Response Distribution, Other, 2011
Figure 4-28: Perceived Brand Purchasing Incentives, 2011
Figure 4-29: Nature of Incentives Received, 2011
Figure 4-30: Reasons to Switch to Different HA Brand, 2011
Figure 4-31: Nature of Incentives Received by Brand Selection Preferences, Asia, 2011
Figure 4-32: Nature of Incentives Received by Brand Selection Preferences, Europe, 2011
Figure 4-33: Nature of Incentives Received by Brand Selection Preferences, Latin America, 2011
Figure 4-34: Nature of Incentives Received by Brand Selection Preferences, Middle East, Africa and Caribbean, 2011
Figure 4-35: Patient Groups Receiving the Most Benefit from HA, 2011
Figure 4-36: Importance of Pricing, 2011
Figure 4-37: Purchasing Channels, 2011
Figure 4-38: Importance of Pricing by Purchasing Channel, Asia, 2011
Figure 4-39: Importance of Pricing by Purchasing Channel, Europe, 2011
Figure 4-40: Importance of Pricing by Purchasing Channel, Latin America, 2011
Figure 4-41: Importance of Pricing by Purchasing Channel, Middle East Africa and Caribbean, 2011
Figure 4-42: Respondent Clinical Setting, 2011
Figure 4-43: Time to Relief After Single Injection Treatment, Weeks, 2011
Figure 4-44: Time to Relief After 3-Injection Treatment, Weeks, 2011
Figure 4-45: Time to Relief After 5-Injection Treatment, Weeks, 2011
APPENDIX 1: SURVEY QUESTIONS
LIST OF CHART'S
EXECUTIVE SUMMARY
Chart 1-1: Hyaluronic Acid Usage Among Survey Respondents, Latin America, 2011
Chart 1-2: Respondent Location by Region, 2011
Chart 1-3: Brand Preference Among, Africa, Middle East and Caribbean, 2011
Chart 1-4: Purchasing Channels, Global, 2011
Chart 1-5: Perceived Importance of Pricing, Global, 2011
Chart 1-6: Likelihood of Increasing Single Injection Use as a function of Satisfaction Rating, Asia, 2011
Chart 1-7: Reasons for Choosing a HA Brand, Europe, 2011
Chart 1-8: Time to Pain Relief in Weeks, 3-Injection Therapy, 2011
SURVEY HIGHLIGHTS
RESEARCH METHODOLOGY
HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS
Chart 4-1: Years of Practice, 2011
Chart 4-2: Respondents by Global Region, 2011
Chart 4-3: Country of Origin, Asia, 2011
Chart 4-4: Country of Origin, Europe, 2011
Chart 4-5: Country of Origin, Latin America, 2011
Chart 4-6: Country of Origin, Africa, Middle East and Caribbean, 2011
Chart 4-7: HA Patients per Month, 2011
Chart 4-8: Monthly HA Patients Seen by Years of Practice, 2011
Chart 4-9: Weighted Average for HA Brand Frequency of Use, Asia, 2011
Chart 4-10: Weighted Average for HA Brand Frequency of Use, Europe, 2011
Chart 4-11: Weighted Average for HA Brand Frequency of Use, Latin America, 2011
Chart 4-12: Weighted Average for HA Brand Frequency of Use, Other, 2011
Chart 4-13: Reasons for Choosing a HA Brand, 2011
Chart 4-14: Reasons for Choosing Brand by Brand Choice, Asia, 2011
Chart 4-15: Reasons for Choosing Brand by Brand Choice, Europe, 2011
Chart 4-16: Reasons for Choosing Brand by Brand Choice, Latin America, 2011
Chart 4-17: Reasons for Choosing Brand by Brand Choice, Middle East, Africa and Caribbean
Chart 4-18: Likelihood of Switching to Single Injection, 2011
Chart 4-19: Satisfaction with Single Injection Products
Chart 4-20: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-21: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-22: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-23: Likelihood of Increasing Single Injection Usage as a Function of Single Injection Satisfaction, 2011
Chart 4-24: Percentage of HA Patients that Subsequently Go on to Total Knee Arthroplasty (TKA), 2011
Chart 4-25: Time to TKA After HA and Conservative Treatments, 2011
Chart 4-26: Time to TKA in Months per Percentage of Patients that Require TKA, Asia, 2011
Chart 4-27: Time to TKA in Months per Percentage of Patients that Require TKA, Europe, 2011
Chart 4-28: Time to TKA in Months per Percentage of Patients that Require TKA, Latin America, 2011
Chart 4-29: Time to TKA in Months per Percentage of Patients that Require TKA, Africa, Middle East and Caribbean, 2011
Chart 4-30: HA Injection Types Used Before TKA, Weighted Average, 2011
Chart 4-31: Perceived Brand Purchasing Incentives, 2011
Chart 4-32: Nature of Incentives Received, 2011
Chart 4-33: Reasons to Switch to Different HA Brand, 2011
Chart 4-34: Patient Groups Receiving the Most Benefit from HA, 2011
Chart 4-35: Importance of Pricing, 2011
Chart 4-36: Purchasing Channels, 2011
Chart 4-37: Respondent Clinical Setting, 2011
APPENDIX 1: SURVEY QUESTIONS
